Agenus Inc (AGEN)
Agenus Inc. is a NASDAQ-listed common stock issuer in the healthcare sector that operates as a clinical-stage biotechnology company focused on therapies designed to stimulate the immune system in the fight against cancer and infectious diseases. The company’s work includes antibody discovery and display technologies such as Retrocyte Display, as well as the development of QS-21 Stimulon, a saponin-based vaccine adjuvant. Its pipeline includes several immuno-oncology programs, among them balstilimab, AGEN1181, AGEN2373, AGEN1423, AGEN1571, and AGEN1884, along with partnered or collaborative programs such as BMS-986442, INCAGN1876, INCAGN2390, INCAGN2385, MK-4830, and UGN-301. Agenus conducts business in the United States and internationally and maintains collaborations with companies including Bristol-Myers Squibb, Betta Pharmaceuticals, UroGen Pharma, Gilead Sciences, Incyte, and Merck Sharp & Dohme. Founded in 1994 and headquartered in Lexington, Massachusetts, the company was previously known as Antigenics Inc. before adopting the Agenus name in 2011.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-AGEN
|
$7.54
|
5.7% Upside
|
Fair
|
$19.50
|
173.5% Upside
|
Bargain
|
Good
|
0.0%
|
November 10, 2026
|
3.5x
|
2.4x
|
324.6 M
|
312.4 M
|
11.4%
|
89.4%
|
-19.6
|
-107.3%
|
